Should I Wait for Retatrutide? How Doctors Are Counseling

The question comes up in every weight-loss medicine practice now: "I heard about retatrutide — should I wait for it instead of starting tirzepatide?"

It's a reasonable question. The Phase 2 data for retatrutide was striking enough that it got published in the New England Journal of Medicine in July 2023, which doesn't happen for every drug in trials. A mean weight loss of 24.2% of body weight at 48 weeks on the highest dose was the number that circulated. Tirzepatide — currently the most effective GLP-1 drug available — achieves roughly 21–22% over 72 weeks at its highest dose. The gap sounds modest, but the shorter timeline in the Phase 2 study generated genuine interest.

Here's what most doctors counseling on this question are actually saying.

What retatrutide's data actually shows

Before weighing the wait, it helps to be honest about what we know and what we don't.

What we know:

• Phase 2 (NEJM, 2023): 338 adults with obesity, 48-week trial, once-weekly subcutaneous injection
• At 12 mg weekly (highest dose): mean body weight loss of 24.2%
• Dose-dependent response: 4 mg produced ~8%, 8 mg produced ~17%, 12 mg produced ~24%
• Gastrointestinal adverse events were dose-dependent and common (70–80% at highest doses), similar in character to tirzepatide and semaglutide but somewhat more frequent at the top dose
• Blood pressure improved; triglycerides improved notably (glucagon agonism increases hepatic fat oxidation)
• Heart rate increased modestly, consistent with the GLP-1 drug class

What we don't know:

• Phase 3 (TRIUMPH program) results — enrollment began in 2024, full data hasn't yet reported
• Whether the 24% figure holds in Phase 3, which typically enrolls a more diverse and harder-to-treat population than Phase 2
• Long-term durability (72-week, 2-year, 5-year outcomes)
• Cardiovascular outcomes — no CVOT data exists for retatrutide (see our retatrutide cardiovascular outcomes guide)
• FDA approval date — still pending Phase 3 completion and NDA submission
• Insurance coverage — which will determine actual patient access after approval
• Long-term safety profile at scale

Phase 2 trials, even well-designed ones, can be optimistic relative to Phase 3. The STEP-1 trial for semaglutide produced its headline 14.9% weight loss in a relatively clean trial population; real-world outcomes have been somewhat lower. The same variability applies to retatrutide.

This isn't pessimism about retatrutide — the mechanism is biologically sound and the Phase 2 results are genuinely impressive. It's intellectual honesty about what we know at this point in development.

What obesity medicine clinicians are actually recommending

Clinicians specializing in obesity medicine broadly advise against waiting for retatrutide when an effective therapy is available now. The reasoning comes from several angles:

Obesity has compounding medical consequences. Every year of continued, untreated obesity at higher BMI levels is not a neutral year. The metabolic sequelae — worsening insulin resistance, progressive fatty liver disease, increasing cardiovascular risk, joint damage, sleep apnea progression — don't pause while waiting for a better drug. The evidence that treating obesity earlier produces better long-term outcomes is consistent across the literature.

You can switch. This is perhaps the most important practical point. Starting tirzepatide now doesn't foreclose retatrutide later. If retatrutide is approved and covered, and the data at that point supports it as a better fit for you, the transition is straightforward: stop tirzepatide, start retatrutide after a brief washout period. Clinicians who've managed semaglutide-to-tirzepatide transitions at scale report that cross-class switches are well-tolerated. The same will almost certainly apply to tirzepatide-to-retatrutide switches.

The approval timeline is uncertain. Based on where the TRIUMPH Phase 3 program appeared to be as of mid-2024, an optimistic estimate for FDA approval is 2027–2028. A conservative estimate is later. Insurance coverage for a newly approved specialty drug typically takes 12–24 months to become widespread across commercial plans and Medicare Part D. Patients who "wait for retatrutide" should be aware they may be waiting 2–4 years from now for a drug they can actually access at an affordable cost.

Partial weight loss now is better than waiting. A patient who starts tirzepatide today and loses 15–20% of body weight by the time retatrutide is available is in a fundamentally different metabolic position than someone who waited. The 3–4% additional theoretical benefit from retatrutide doesn't outweigh 2–3 years of achieved metabolic improvement.

Who might reasonably consider waiting

In fairness to the other side of this conversation, there are specific situations where waiting deserves at least consideration:

Patients with only a small window of access to any drug. Some patients are paying out of pocket and can only afford one major treatment course. If the evidence trajectory suggests retatrutide will offer meaningfully more benefit for their specific situation — particularly if they have a phenotype associated with particularly strong response to glucagon agonism, such as significant hepatic steatosis — a case for waiting has more merit.

Patients who strongly prefer to start once and stay on one therapy. Drug-switching, titrations, and transitions involve periods of side effects and adjustment. Some people reasonably want to minimize that. For these patients, waiting for what may be a more effective first-line agent is a personal preference that isn't unreasonable.

Patients near the access threshold. If a patient's BMI or comorbidity profile currently qualifies them for tirzepatide but they're near the lower end of qualifying criteria, and their metabolic situation is stable and well-managed, a conservative prescriber might reasonably say "the urgency is lower; let's see what the next 12 months of data shows."

These are genuinely uncommon clinical situations. For most patients with obesity-related comorbidities, the "start now, switch if warranted later" path is the one most clinicians recommend.

The steelman for waiting

The most coherent argument for waiting goes like this:

Starting a GLP-1 drug typically involves 16–20 weeks of titration to maintenance dose, a period of significant GI adjustment, potentially periods of nausea or dose reduction. If you're going to go through that adjustment process, you want to do it once, on the drug you'll be on long-term. Retatrutide may offer better durability, better weight loss depth, and possibly better metabolic effects from the glucagon component. The GI adjustment period on retatrutide appears similar in character to other drugs in the class. If you can be reasonably confident retatrutide is 2–3 years away and you're not facing immediate serious metabolic consequences from waiting, doing the adjustment once on the best drug is appealing.

This argument is more compelling for someone with BMI 30 and no active comorbidities than for someone with BMI 42, uncontrolled type 2 diabetes, and cardiovascular disease. The urgency calculus is patient-specific.

The cost and coverage wildcard

One variable that often gets lost in the clinical discussion: price and insurance coverage.

Brand-name tirzepatide (Zepbound) is expensive — list prices have been in the $500–1,000/month range with significant variation based on insurance and coupon programs. Eli Lilly's savings programs have helped some cash-pay patients, but cost remains a barrier.

Retatrutide, as a new branded drug with a novel mechanism, will almost certainly launch at a similar or higher price point. Prior authorization requirements for new obesity drugs are common and can take months to navigate. The expectation that retatrutide will be more affordable or more accessible than tirzepatide shortly after approval is not well-founded.

For patients making decisions partly based on out-of-pocket cost, the near-term picture for retatrutide is not obviously better than the current picture for tirzepatide, and compounded tirzepatide options may actually make the current drug more economically accessible than the future drug for some patients. The retatrutide cost prediction guide covers the insurance trajectory in more detail.

A practical decision framework

If you're genuinely weighing this question, here are the considerations that actually matter:

Favor starting now if:

• You have active metabolic comorbidities (T2D, hypertension, sleep apnea, fatty liver disease)
• Your BMI is above 35
• You're postmenopausal or have high cardiovascular risk
• You can access tirzepatide now at manageable cost
• You understand you can switch to retatrutide if it's approved and indicated

The waiting case is stronger if:

• Your metabolic situation is stable with minimal active comorbidities
• You're paying fully out of pocket and can only afford one serious drug course
• Your BMI and risk profile allow a 2–3 year pause without meaningful harm
• You have access to good lifestyle support (diet, exercise coaching) that can partially offset the delay

The bottom line from most obesity medicine specialists: the weight loss retatrutide might offer over tirzepatide is real but uncertain, and the benefit of treating obesity now is certain. Most clinicians advise starting what's available, doing it well, and revisiting the choice when the Phase 3 data is in and the drug is actually accessible.

Related reading

• Retatrutide vs Tirzepatide: Head-to-Head Comparison
• Retatrutide FDA Approval Timeline
• Retatrutide Cardiovascular Outcomes
• Tirzepatide: The Complete Guide
• Retatrutide Cost Prediction